Article

Applied Clinical Trials

Catalent Selected to Provide Oral Delivery Systems

GB Sciences, Inc. and Catalent Pharma Solutions, a global provider of delivery technologies and development solutions, announced that GB Sciences has selected Catalent to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacturing of GB Sciences’ proprietary active pharmaceutical ingredients for its Parkinson’s disease therapies.

Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
Related Content
Credit: kentoh | stock.adobe.com. The development of digital tools and wearable sensors, along with real-time data collection and a growing commitment to patient centricity, has propelled a shift toward decentralized clinical trials
August 29th 2025

Reimagining Clinical Trials for Remote Populations

Matthew Noble
ACT Brief Episode 6: Supreme Court Ruling, VK2735 Obesity Trial, and Padcev-Keytruda Survival Gains
August 29th 2025

ACT Brief Episode 6: Supreme Court Ruling, VK2735 Obesity Trial, and Padcev-Keytruda Survival Gains

Andy Studna, Senior Editor
© JHVEPhoto - © JHVEPhoto - stock.adobe.com
August 29th 2025

FDA Authorizes New COVID Vaccines with Restrictions on Eligibility

Davy James
ACT Brief Episode 5: How Digital Twins and AI Are Reshaping Clinical Trials
August 29th 2025

ACT Brief Episode 5: How Digital Twins and AI Are Reshaping Clinical Trials

Andy Studna, Senior Editor
Credit: photon_photo | stock.adobe.com. Clinical trial success depends on selecting appropriate clinical sites. Poor site selection can lead to delayed recruitment, compromised data quality, increased costs, and regulatory risks
August 29th 2025

Beyond Prediction: An Evidence-Based Framework for Assessing Site Selection Decisions

Anh Ninh, Linh Nguyen and Daniel Butler
Credit: Dzmitry | stock.adobe.com. SMA can range from severe cases that develop during infancy to milder forms of the disease that manifest later in life.
August 29th 2025

Evrysdi Helps Presymptomatic Infants with Spinal Muscular Atrophy Sit, Stand, and Walk in Phase II Trial

Davy James
© 2025 MJH Life Sciences

All rights reserved.